←
BeCytes Biotechnologies452 posts
BeCytes Biotechnologies avatar

BeCytes Biotechnologies

@CytesB

Experts in Human Liver Cells & Tissue Sourcing

◷ Joined October 2018▧ 263 Photos and videos
BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·27 Feb 2025

These steps can help maintain the integrity of your organoid cultures and ensure more accurate experimental results. 👋🏼 Say goodbye to sticky problems and hello to smoother workflows.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·27 Feb 2025

One big mistake when handling organoids: Not pre-wetting pipet tips. We have compiled insights from our scientific partners:  ↳ Use a new tip for each transfer. ↳ If sticking persists, prepare a 0.5-1% BSA in DMEM:F12 solution and sterile filter it.

Post attachmentPost attachment
BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·25 Feb 2025

BeCytes Biotechnologies accounts on a logistic network that allows us to deliver samples worldwide and fresh samples within 24 hours in the European Union and the US.  We achieve our global coverage directly or through our trusted partners and distributors.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·25 Feb 2025

🚚 How to make sure your cells arrive fresh in less than 24 hours.   Delays can ruin your experiments and cost you money. We understand the frustration of receiving unfrozen samples.  BeCytes Biotechnologies ensures timely delivery.

0:36
BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·20 Feb 2025

Following the successful optimization of organoid culture technology, some progress has been made over the past years in modeling liver-specific rare genetic diseases using the organoid platform.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·20 Feb 2025

These are the key challenges in rare disease research: 1️⃣ Limited funding:  Resources are scarce and often misallocated. Rare diseases affect so few people that it is not cost-effective to research them.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·20 Feb 2025

Let’s face it, despite rare diseases affecting millions, there is a problem.  300 million people live with rare diseases. By definition, rare diseases affect a small number of individuals (fewer than 1 in 2000 people). However, most are overlooked and lack research.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·13 Feb 2025

❄️ Cryopreserved vs fresh hepatocytes can make a big difference. ↳ Cryopreserved cells are ready to use when you need them, reducing waiting times. ↳ Fresh cells maintain a native physiological state.  Do you use them fresh or cryopreserved?

Post attachment
BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·11 Feb 2025

🔵 These procured samples will enable the isolation of cell types, to create a highly relevant human lung tissue model, incorporating an immune component. All protocols for cell isolation and characterization have been developed after years of intense research by our R&D team.

Post attachment
BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·11 Feb 2025

💡 How are we going to do it? As experts in tissue procurement, BeCytes Biotechnologies will establish tissue procurement networks with hospitals, facilitating access to lung tissues and corresponding blood samples from the same donors.

BeCytes Biotechnologies avatar
BeCytes Biotechnologies@CytesB·11 Feb 2025

→ 5. AI-driven predictions An AI system will predict safety outcomes, reducing the need for additional testing steps and making the process more efficient.